Augmedix Reports $10.8M Revenue in Q2 2023

The FDA should require clinical trials in perioperative therapy for non-small cell lung cancer (NSCLC) to address the individual contributions of neoadjuvant and adjuvant treatment

Mod­er­na is join­ing an­oth­er Op­er­a­tion Warp Speed ini­tia­tive — this time, for rare dis­eases. The biotech’s mR­NA can­di­date for a pro­tein and lipid me­tab­o­lism dis­or­der